Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells

Neurosurgery

Volumn 65, Issue 3, 2009, Pages 610-624

  Yang, Bojie ^a   Wu, Xing ^a   Mao, Ying ^a   Bao, Weiming ^a   Gao, Liang ^a   Zhou, Ping ^a   Xie, Rong ^a   Zhou, Liangfu ^a   Zhu, Jianhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis inducing ligand; Gene therapy; Glioma; Mesenchymal stem cell; Migration; Tumor necrosis factor related

Indexed keywords

PARVOVIRUS VECTOR; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN STEM; CELL MIGRATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; BRAIN STEM NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; GLIOMA; HUMANS; IN SITU NICK-END LABELING; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, SMALL INTERFERING; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69549113506     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000350227.61132.A7     Document Type: Article

References (65)

1. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97:12846-12851, 2000. (Pubitemid 30840504)
2. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66:9054-9064, 2006. (Pubitemid 44521124)
3. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, Frank JA: Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105:420-425, 2005. (Pubitemid 40053114)
4. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430, 2002.
5. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 281:1305-1308, 1998.
6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162, 1999.
7. Barbero S, Bajetto A, Bonavia R, Porcile C, Piccioli P, Pirani P, Ravetti JL, Zona G, Spaziante R, Florio T, Schettini G: Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann N Y Acad Sci 973:60-69, 2002. (Pubitemid 36124978)
8. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42-48, 2002. (Pubitemid 34059216)
9. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, Vescovi A, Cattaneo E, Finocchiaro G: Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6:447-450, 2000. (Pubitemid 30208163)
10. Bianco P, Riminucci M, Gronthos S, Robey PG: Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells 19:180-192, 2001. (Pubitemid 32524539)
11. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864, 2004. (Pubitemid 39070860)
12. Colter DC, Class R, DiGirolamo CM, Prockop DJ: Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A 97:3213-3218, 2000. (Pubitemid 30183281)
13. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843, 2002. (Pubitemid 34534559)
14. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jorgensen C: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837-3844, 2003. (Pubitemid 37409409)
15. Donaldson SS, Laningham F, Fisher PG: Advances toward an understanding of brainstem gliomas. J Clin Oncol 24:1266-1272, 2006. (Pubitemid 46622029)
16. Dörr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, Nitsch R, Zipp F: Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci 22:RC209, 2002.
17. Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK: Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107:2774-2776, 2006.
18. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JS: Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62:7170-7174, 2002. (Pubitemid 36025232)
19. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS: The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62:5657-5663, 2002. (Pubitemid 35204717)
20. Ehtesham M, Yuan X, Kabos P, Chung NH, Liu G, Akasaki Y, Black KL, Yu JS: Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 6:287-293, 2004. (Pubitemid 38657085)
21. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885, 2005. (Pubitemid 41746032)
22. Fulda S, Wick W, Weller M, Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815, 2002. (Pubitemid 34887244)
23. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC: Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res 61:1162-1170, 2001. (Pubitemid 32174439)
24. Hargrave D, Bartels U, Bouffet E: Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol 7:241-248, 2006. (Pubitemid 43286454)
25. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI: Characterization of cells with osteogenic potential from human marrow. Bone 13:81-88, 1992.
26. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY, Khoury SJ: Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 101:18117-18122, 2004. (Pubitemid 40054083)
27. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61:3330-3338, 2001. (Pubitemid 32695022)
28. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A: Receptor-selective mutants of apoptosisinducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205-2212, 2005.
29. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38, 2001. (Pubitemid 32905115)
30. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ: Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20:5789-5798, 2001. (Pubitemid 32937948)
31. Kopen GC, Prockop DJ, Phinney DG: Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 96:10711-10716, 1999.
32. Kørbling M, Estrov Z: Adult stem cells for tissue repair-a new therapeutic concept? N Engl J Med 349:570-582, 2003. (Pubitemid 36951370)
33. Lee J, Hampl M, Albert P, Fine HA: Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4:312-323, 2002. (Pubitemid 34755841)
34. Lopez Ponte A, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J: The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737-1745, 2007. (Pubitemid 47121852)
35. Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin B, Posner M, Rosenfelder D, Watson C: Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5:41-55, 1994. (Pubitemid 24310534)
36. Machein MR, Renninger S, de Lima-Hahn E, Plate KH: Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13:582-597, 2003. (Pubitemid 37420701)
37. Menon LG, Picinich S, Koneru R, Gao H, Lin SY, Koneru M, Mayer-Kuckuk P, Glod J, Banerjee D: Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 25:520-528, 2007. (Pubitemid 46232808)
38. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318, 2005. (Pubitemid 40524615)
39. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11:1155-1164, 2004. (Pubitemid 39117311)
40. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818, 1997. (Pubitemid 27366732)
41. Péron JM, Bureau C, Gourdy P, Lulka H, Souque A, Calippe B, Selves J, Al Saati T, Bernad J, Cordelier P, Couderc B, Pradayrol L, Pipy B, Buscail L, Vinel JP: Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: A role for peritoneal innate immunity. Gut 56:107-114, 2007. (Pubitemid 46044896)
42. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C: Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261-262, 2005. (Pubitemid 40460552)
43. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690, 1996. (Pubitemid 26175834)
44. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P: Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171:3426-3434, 2003. (Pubitemid 37254543)
45. Rempel SA, Dudas S, Ge S, Gutierrez JA: Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6:102-111, 2000. (Pubitemid 30064982)
46. Rieger J, Ohgaki H, Kleihues P, Weller M: Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol 97:1-4, 1999. (Pubitemid 29132639)
47. Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M: Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265:479-483, 1999.
48. Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V, Benezra R: Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4:277-289, 2003. (Pubitemid 37329792)
49. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, Aboody K, Padovan C, Straube A, Tonn JC, Goldbrunner R: Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 199:301-310, 2006. (Pubitemid 44202456)
50. Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D, Beveren CV, Wilson D: Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum Gene Ther 6:195-204, 1995.
51. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A: Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor- 1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24:1254-1264, 2006. (Pubitemid 44464694)
52. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L: Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106:419-427, 2005. (Pubitemid 40981232)
53. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608, 2002. (Pubitemid 34728832)
54. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603, 2004. (Pubitemid 39534883)
55. Suminami Y, Elder EM, Lotze MT, Whiteside TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol 17:238-248, 1995.
56. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 6:1607-1624, 1995. (Pubitemid 26014571)
57. Tocci A, Forte L: Mesenchymal stem cell: Use and perspectives. Hematol J 4:92-96, 2003. (Pubitemid 36748510)
58. Veelken H, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A: A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269-277, 1997. (Pubitemid 27099593)
59. Voelkel-Johnson C, King DL, Norris JS: Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 9:164-172, 2002. (Pubitemid 34141919)
60. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163, 1999. (Pubitemid 29068521)
61. Wang T, Xia D, Li N, Wang C, Chen T, Wan T, Chen G, Cao X: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis. J Biol Chem 280:4374-4382, 2005. (Pubitemid 41741357)
62. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995. (Pubitemid 26091143)
63. Woodbury D, Schwarz EJ, Prockop DJ, Black IB: Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61:364-370, 2000. (Pubitemid 30620221)
64. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I: A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104:2643-2645, 2004. (Pubitemid 39434942)
65. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y: Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80:267-274, 2006.